TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8831216
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml Iopamidol (300 mgI/ml), at a rate of 2 ml/sec
Study: 8831216
Drug: 120 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 ml, 3 ml/sec
Study: 8831216
Drug: 150 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml, 3 ml/sec
Study: 8831216
Drug: biphasic method,
Approvals — FDA: no, EMA: no, PMDA: no
Description: biphasic method, initial 100 ml, 3.3 ml/sec; remaining 50 ml, 1.6 ml/sec
Study: 2248385
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine and clonidine (group 1; n = 45)
Study: 2248385
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine alone (group 2; n = 46)
Study: 7437248
Drug: Colchicine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.0 mg daily for 8 days)
Study: 7437248
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 8 days)
Study: 30461542
Drug: Rituximab and
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab and Tumor Necrosis Factor Inhibitors (including Certolizumab)
Study: 26708726
Drug: Intradialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic parenteral nutrition (IDPN) plus standardized nutritional counseling
Study: 25467396
Drug: Mental practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental practice (MP) and mirror therapy (MT) associated with conventional physical therapy training (CPTT)
Study: 22788263
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release (GXR) added to stimulant monotherapy
Study: 20837589
Drug: Stimulant monotherapy
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant monotherapy
Study: 1611460
Drug: Dietary calcium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary calcium supplementation (1.25 g day‐1)
Study: 31371195
Drug: Ultrasound-guided lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided lumbar plexus and sciatic nerve blocks with ropivacaine (1.5 mg kg‐1)
Study: 27765750
Drug: High-dose ebselen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ebselen (150 mg po twice daily)
Study: 19902197
Drug: Racecadotril 100
Normalized name: racecadotril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril 100 mg every 8 h
Study: 19902197
Drug: Loperamide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2.0 mg followed by one tablet after each unformed stool, up to four tablets in any 24-h period
Study: 17923225
Drug: Self‐etching primer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐etching primer (CSE) with 20% polyacrylic acid conditioner (Cavity conditioner, CC) preconditioning after TM application
Study: 9620116
Drug: PHT sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT sodium solution 435 mg intravenously
Study: 9620116
Drug: PHT acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT acid suspension 400 mg
Study: 9620116
Drug: PHT sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT sodium solution 435 mg
Study: 2191992
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of methylprednisolone (40 mg bolus)
Study: 2191992
Drug: Divided regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided regimen of methylprednisolone (20 mg bolus and 5 mg bolus 8 hours later)
Study: 475363
Drug: Aminoglycoside treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside treatment (gentamicin, tobramycin, or amikacin)
Study: 31679069
Drug: Treatment-as-usual (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (2 weeks of unloading in plaster cast followed by 4 weeks weightbearing in orthosis)
Study: 28072888
Drug: Early on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early on-treatment response at Week 4
Study: 17623958
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA tramadol (loading dose of 2.5 mg/kg followed by PCA infusion of 10 mg)
Study: 17623958
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA morphine (loading dose of 0.1 mg/kg followed by PCA morphine bolus of 1 mg)
Study: 17623958
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA tramadol
Study: 17623958
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA morphine
Study: 11157376
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of warfarin daily for 12 months
Study: 11157376
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 29)
Study: 9395349
Drug: Zanamivir (GG167)
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir (GG167) intranasally as early treatment
Study: 8203783
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (micronized flavonoidic fraction)
Study: 3302568
Drug: Naftidrofuryl (Dusodril)
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (Dusodril) in combination with cortison and dextran
Study: 3302568
Drug: Pentoxifyllin (Trental)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifyllin (Trental) in combination with cortison and dextran
Study: 3302568
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with either naftidrofuryl or pentoxifyllin
Study: 29495483
Drug: Household water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household water treatment systems (biosand zeolite-silver impregnated granular clay filters and silver-impregnated porous pot filters) installed in 372 participants from 70 households.
Study: 24622667
Drug: Stepwise addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise addition of bolus insulin (one bolus dose with the largest meal, additional doses at 11 and 22 weeks if HbA1c remained at 7% or higher)
Study: 24622667
Drug: Full basal-bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full basal-bolus therapy (insulin aspart before every meal)
Study: 19437243
Drug: Guided active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided active play/physical activity, 60 minutes, twice a week for 5 months
Study: 15769980
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg dexamethasone twice daily for 5 days
Study: 10401515
Drug: Naloxone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0, 0.8, 1.6, or 3.2 mg/70 kg)
Study: 10401515
Drug: Naloxone (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (lower doses)
Study: 1693037
Drug: Allylestrenol (ALE)
Normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allylestrenol (ALE) 50 mg/day for 12 weeks
Study: 1693037
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) 50 mg/day for 12 weeks
Study: 331522
Drug: Fluorouracil intraluminal
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil intraluminal chemotherapy
Study: 30949704
Drug: Intravenous lefamulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lefamulin (150 mg, q12h)
Study: 30949704
Drug: Oral lefamulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lefamulin (600 mg IR tablet)
Study: 30949704
Drug: Oral lefamulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lefamulin (3 × 200 mg capsule)
Study: 30949704
Drug: Oral lefamulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lefamulin (IR) in fasted state
Study: 30949704
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of lefamulin (IR, q12h)
Study: 26209860
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg/d)
Study: 26209860
Drug: Amisulpride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200 mg/d)
Study: 21611863
Drug: Group Slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Slow (1 ml/min injection of hyperbaric 0.5% bupivacaine)
Study: 21611863
Drug: Group Extra
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Extra Slow (0.5 ml/min injection of hyperbaric 0.5% bupivacaine)
Study: 19912734
Drug: Sanxue Mingmu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanxue Mingmu Tablet combined with conventional treatment
Study: 19912734
Drug: Xueshuantong Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuantong Tablet combined with conventional treatment
Study: 16698412
Drug: Intranasal lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lorazepam (100 microg/kg)
Study: 16698412
Drug: Intramuscular paraldehyde
Normalized name: Paraldehyde
DrugBank: Paraldehyde (DB09117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular paraldehyde (0.2 mL/kg)
Study: 15138466
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy as perceived by medical oncologists
Study: 11336276
Drug: Thin-layer chromatography
Normalized name: Bayer Aspirin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin-layer chromatography (TLC) screening method for drug quality
Study: 9466167
Drug: RS-8359 100
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-8359 100 mg/day
Study: 9466167
Drug: RS-8359 200
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-8359 200 mg/day
Study: 8923574
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 mg/day
Study: 9466167
Drug: RS-8359 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-8359 (all doses)
Study: 23926589
Drug: 11 different
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 different toothbrushes (Colgate Massager, Butler 311, Gum Super Tip 463, Oral-B Indicator 35, Colgate Omni, Gum Technique 493)
Study: 23926589
Drug: Oral-B Indicator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B Indicator 35
Study: 2895695
Drug: Beta 2-antagonist
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-antagonist pretreatment
Study: 31221941
Drug: Leukocytapheresis (LCAP)
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytapheresis (LCAP) therapy (n = 20)
Study: 31221941
Drug: Disease-modifying antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying antirheumatic drugs (DMARDs) (n = 31)
Study: 30621787
Drug: Back2School (modular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Back2School (modular transdiagnostic cognitive behavioral therapy)
Study: 21178123
Drug: Glycerol mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol mixed with cranberry juice (97 ± 3 ml glycerol + equal portion of cranberry juice; n = 9)
Study: 18778333
Drug: Moxaverine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxaverine (150 mg, administered i.v.)
Study: 15240597
Drug: Nutropin Depot
Normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutropin Depot 0.75 mg/kg once per month
Study: 15240597
Drug: Nutropin Depot
Normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutropin Depot 0.75 mg/kg twice per month
Study: 15240597
Drug: Nutropin Depot
Normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutropin Depot 1.5 mg/kg once per month
Study: 15240597
Drug: Nutropin Depot
Normalized name: Nutropin Depot
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutropin Depot (all dosing regimens)
Study: 9722130
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day for 10 consecutive days starting on the 13th day of the menstrual cycle
Study: 8002320
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg, increased to 40 mg based on response)
Study: 18835927
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to fluoxetine)
Study: 3404502
Drug: Dentist-administered ultrasound
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentist-administered ultrasound
Study: 27560168
Drug: pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks)
Study: 20598974
Drug: Elinogrel (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinogrel (intravenous and oral formulations)
Study: 11136293
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg microencapsulated octreotide acetate intramuscularly
Study: 8799516
Drug: Intravenous phylloquinone
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Study: 8799516
Drug: Intramuscular phylloquinone
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Study: 1629383
Drug: Alprazolam (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (average maximum dosage 2.2 mg)
Study: 1629383
Drug: Imipramine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (average maximum dosage 97.5 mg)
Study: 6483520
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline sprinkle preparation (fasting)
Study: 6483520
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline sprinkle preparation (after standardized meal)
Study: 29537451
Drug: Sarecycline 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarecycline 1.5 mg/kg
Study: 29537451
Drug: Sarecycline 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarecycline 3.0 mg/kg
Study: 28139568
Drug: Combined chemoradiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemoradiotherapy (CRT) with 75 mg/m2 temozolomide (TMZ) followed by 200 mg/m2 TMZ for 5 days every 28 days
Study: 20054294
Drug: Repaglinide treatment
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide treatment for 8 weeks
Study: 20039413
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg) administered on days 1, 15, 168, and 182
Study: 10894282
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily with either Zidovudine/Lamivudine (49%), Stavudine/Lamivudine (38%), or Stavudine/Didanosine (13%)
Study: 10894282
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily
Study: 10894282
Drug: Ritonavir/Indinavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir/Indinavir plus double nucleoside therapy
Study: 8669994
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment program (daily physiotherapy)
Study: 8669994
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment program
Study: 1508127
Drug: Flurbiprofen 300
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 300 mg/day, orally, starting the day before surgery and continuing for 7 consecutive days
Study: 6308755
Drug: Pivmecillinam-pivampicillin (PMPA)
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam-pivampicillin (PMPA) 200 + 250 mg b.i.d.
Study: 6308755
Drug: Pivmecillinam (PM)
DrugBank: Pivmecillinam (DB01605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam (PM) 400 mg b.i.d.
Study: 31974708
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (POCT)
Study: 29241383
Drug: 600 µg buccal
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 µg buccal misoprostol
Study: 29241383
Drug: 1000 mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg oral TA plus 600 µg buccal misoprostol
Study: 16495394
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg once weekly)
Study: 15857102
Drug: 1.50 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.50 mg/ml rhBMP‐2/ACS
Study: 15857102
Drug: 0.75 mg/ml
Normalized name: digoxin 0.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/ml rhBMP‐2/ACS
Study: 16048928
Drug: Ertapenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1 g once a day)
Study: 12183244
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g daily)
Study: 10968433
Drug: Omapatrilat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (40 mg daily for 24 weeks)
Study: 10968433
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg daily for 24 weeks)
Study: 1453199
Drug: Progesterone receptor-positive
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone receptor-positive (PgR+) status and decreasing tumor size
Study: 4095819
Drug: Glipizide, 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide, 1.25 mg daily added at breakfast for 10 subjects after 6 months of dietary and exercise treatment
Study: 4095819
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (18 GI subjects) with no treatment for 5-10 months
Study: 21711479
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once-a-day
Study: 24784894
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg on demand
Study: 24784894
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg on demand
Study: 22307061
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (CCRT) with adjuvant chemotherapy (Paclitaxel 135 mg/m² + Cisplatin 75 mg/m²)
Study: 22307061
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (CCRT) alone
Study: 19957087
Drug: PETN 80
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PETN 80 mg t.i.d.
Study: 12021739
Drug: Naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone treatment (10 mg)
Study: 2086017
Drug: Aspirin 20mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 20mg/d
Study: 2086017
Drug: Diltiazem plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem plus Aspirin
Study: 31065992
Drug: Oxycodone ARIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone ARIR 30 mg under fasted conditions
Study: 31065992
Drug: Oxycodone ARIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone ARIR 30 mg under fed conditions
Study: 31065992
Drug: IR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR oxycodone 30 mg under fasted conditions
Study: 23084077
Drug: Lutein-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein-based oral supplement
Study: 23084077
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (non-treated group)
Study: 16908788
Drug: Varenicline tartrate
Normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline tartrate 1.0 mg twice daily
Study: 16908788
Drug: Varenicline tartrate
Normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline tartrate 1.0 mg once daily
Study: 16908788
Drug: Bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion hydrochloride 150 mg twice daily
Study: 11558289
Drug: CEA with
Normalized name: Radiance Echinacea with Goldenseal Root Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA with patching (PTFE or vein patch closure)
Study: 11558289
Drug: Patching using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching using PTFE or vein patch closure
Study: 11558289
Drug: Hemashield patch
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemashield patch
Study: 29061382
Drug: Daily meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meal distribution approach
Study: 24665971
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg F/g with 1% TMP
Study: 24665971
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg F/g with 0.25% CaGP
Study: 24665971
Drug: 1100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1100 μg F/g
Study: 20823381
Drug: Achieved on‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieved on‐treatment systolic BP levels in the first 24 hours
Study: 18491071
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (daily docosahexaenoic/eicosapentaenoic acid capsules, no other seafood; single-blinded)